Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Show all species
Show all synonyms
Select your species and application
anti-Human PLAU Antibodies:
anti-Mouse (Murine) PLAU Antibodies:
anti-Rat (Rattus) PLAU Antibodies:
Go to our pre-filtered search.
Human Polyclonal PLAU Primary Antibody for FACS, IHC (p) - ABIN1882148
Strausberg, Feingold, Grouse, Derge, Klausner, Collins, Wagner, Shenmen, Schuler, Altschul, Zeeberg, Buetow, Schaefer, Bhat, Hopkins, Jordan, Moore, Max, Wang, Hsieh, Diatchenko, Marusina, Farmer et al.: Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences. ... in Proceedings of the National Academy of Sciences of the United States of America 2002
Show all 8 Pubmed References
Mouse (Murine) Monoclonal PLAU Primary Antibody for ELISA (Capture), ELISA (Detection) - ABIN491262
Botkjaer, Deryugina, Dupont, Gårdsvoll, Bekes, Thuesen, Chen, Chen, Ploug, Quigley, Andreasen: Targeting tumor cell invasion and dissemination in vivo by an aptamer that inhibits urokinase-type plasminogen activator through a novel multifunctional mechanism. in Molecular cancer research : MCR 2012
Show all 3 Pubmed References
Human Monoclonal PLAU Primary Antibody for ELISA (Capture), ELISA (Detection) - ABIN491259
Florova, Azghani, Karandashova, Schaefer, Koenig, Stewart-Evans, Declerck, Idell, Komissarov: Targeting of plasminogen activator inhibitor 1 improves fibrinolytic therapy for tetracycline-induced pleural injury in rabbits. in American journal of respiratory cell and molecular biology 2015
Show all 2 Pubmed References
Human Polyclonal PLAU Primary Antibody for EIA, IHC (fro) - ABIN191518
Coy, Jiménez-Movilla, García-Vázquez, Mondéjar, Grullón, Romar: Oocytes use the plasminogen-plasmin system to remove supernumerary spermatozoa. in Human reproduction (Oxford, England) 2012
Human Polyclonal PLAU Primary Antibody for IHC (p), IHC - ABIN439170
Lee, Oh, Park, Na, Gil, Yang, Lee, Hong: Urokinase, urokinase receptor, and plasminogen activator inhibitor-1 expression on podocytes in immunoglobulin A glomerulonephritis. in The Korean journal of internal medicine 2014
Human Polyclonal PLAU Primary Antibody for ELISA, WB - ABIN250818
Morgan, Hill: Human breast cancer cell-mediated bone collagen degradation requires plasminogen activation and matrix metalloproteinase activity. in Cancer cell international 2005
Mouse (Murine) Polyclonal PLAU Primary Antibody for ELISA (Detection), IHC (fro) - ABIN491326
Zhang, Kernan, Thomas, Collins, Song, Li, Zhu, Leboeuf, Eddy: A novel signaling pathway: fibroblast nicotinic receptor alpha1 binds urokinase and promotes renal fibrosis. in The Journal of biological chemistry 2009
Human Polyclonal PLAU Primary Antibody for ELISA, WB - ABIN2477037
Woo, OBrien, Gillies, Etheridge: Mechanical and radiation isocenter coincidence: an experience in linear accelerator alignment. in Medical physics 1992
Show all 2 Pubmed References
Increased expression of uPA (show PRAP1 Antibodies) in epidermal cells in psoriasis and in tumor cells in basal cell carcinomas suggests an important role of the uPA (show PRAP1 Antibodies) system for aggressively proliferating and invading cells of epidermal origin.
study provides strong support in the role of L. reuteri in suppression of GC cell invasion by downregulation of pathways which is involved in extracellular matrix degradation such as uPA (show PRAP1 Antibodies) and uPAR (show PLAUR Antibodies)
uPA (show PRAP1 Antibodies) protection is independent of its catalytic activity, as the amino terminal fragment of uPA (show PRAP1 Antibodies) showed similar protection. A key enzyme for repairing oxidative DNA damage is the p53 (show TP53 Antibodies) target hOGG1. We found a significant increase of hOGG1 after pretreatment of HACM with uPA (show PRAP1 Antibodies). Knockdown of hOGG1 completely abrogated the protective effect of uPA (show PRAP1 Antibodies)
We show that the tumor-suppressive actions of MEPs are mediated by PAI-1 (show SERPINE1 Antibodies), uPA (show PRAP1 Antibodies) and its receptor, uPAR (show PLAUR Antibodies), and are sustained even in the presence of the CAFs (show TBX1 Antibodies), which themselves enhance DCIS tumorigenesis via IL-6 (show IL6 Antibodies) signaling.
Gelsolin (show GSN Antibodies) enhances the invasive capacity of colon cancer cells via elevating intracellular superoxide (O2.-) levels by interacting with Cu/ZnSOD (show SOD1 Antibodies), and gelsolin (show GSN Antibodies) gene expression positively correlates with urokinase plasminogen (show PLG Antibodies) activator (uPA (show PRAP1 Antibodies)), an important matrix-degrading protease invovled in cancer invasion.
the optimal discrimination cut-off for each cytokine: sVEGFR-1 (2124.5pg/mL), IL-6 (show IL6 Antibodies) (40.2pg/mL), VEGF-A (show VEGFA Antibodies) (1060.1pg/mL), Angiopoeintin-2 (913.7pg/mL), uPA (show PRAP1 Antibodies) (248.1pg/mL), sHER-2/neu (show ERBB2 Antibodies) (5010pg/mL) and PLGF (show PGF Antibodies) (93.4pg/mL). For the very first time, a novel cytokine profile associated with cancer metastasis to the paratracheal lymph nodes were reported.
Study provides evidence that the stimulation of u-PA/u-PAR (show PLAUR Antibodies) system contributes to the activated phenotype and function of cancer-associated fibroblasts during multiple myeloma.
OB-Rb (show LEPR Antibodies), RhoA (show RHOA Antibodies)/ROCK, PI3K (show PIK3CA Antibodies)/AKT (show AKT1 Antibodies), JAK (show JAK3 Antibodies)/STAT (show STAT1 Antibodies) pathways and NF-kB activation are involved in leptin (show LEP Antibodies)-induced upA (show PRAP1 Antibodies) expression.
Results provide evidence that uPA (show PRAP1 Antibodies) and IGF1R (show IGF1R Antibodies) directly interact with uPAR (show PLAUR Antibodies) enhancing malignant potential of triple-negative breast cancer.
suggest that the low endogenous levels of uPA (show PRAP1 Antibodies) in blood are actively regulated, and that the regulatory mechanisms are disrupted in QPD in a megakaryocyte-specific manner
data presented here reveal important information about dynamics in uPA by demonstrating how various ligands can modulate uPA activity by mediating long-range conformational changes
Lymphangioleiomyomatosis is fatal lung disease associated with germline/somatic inactivating mutations in TSC2 (show TSC2 Antibodies) genes. Data suggest lung lymphangioleiomyomatosis lesions and renal angiomyolipomas overexpress uPA; Tsc2 (show TSC2 Antibodies)-/- (or Tsc1 (show TSC1 Antibodies)-/-) embryonic fibroblasts from knockout mice express higher uPA levels than wild-type cells. (uPA = urokinase-type plasminogen activator; Tsc (show SLC12A3 Antibodies) = tuberous sclerosis complex protein)
The findings suggest that the absence of uPA correlates with increased levels of Runx transcriptional regulators in a way that promotes inflammation-associated carcinogenesis.
an intricate link between caveolin-1 (show CAV1 Antibodies) and Src kinase (show CSK Antibodies)-mediated cell signaling and alveolar epithelial cell apoptosis due to loss of SP-C (show SFTPC Antibodies) expression through p53 (show TP53 Antibodies) and uPA system-mediated cross-talk, is reported.
These studies identify uPA-dependent de-repression of vegfr1 (show FLT1 Antibodies) and vegfr2 (show KDR Antibodies) gene transcription through binding to HHEX/PRH (show HHEX Antibodies) as a novel mechanism by which uPA mediates the pro-angiogenic effects of VEGF (show VEGFA Antibodies) and identifies a potential new target for control of pathologic angiogenesis.
Significance of the urokinase-type plasminogen activator and its receptor in the progression of focal segmental glomerulosclerosis in clinical and mouse models.
GM-CSF (show CSF2 Antibodies) and uPA are required for Porphyromonas gingivalis-induced alveolar bone loss in a mouse periodontitis model.
Plau deficiency does not worsen controlled cortical impact-induced brain pathology or epileptogenesis caused by TBI.
we have firstly shown a fundamental mechanism of urokinase system(uPa and uPAR (show PLAUR Antibodies))-dependent regulation of the trajectory of growth and branching of blood vessels in early embryogenesis and in adults during the repair/regeneration of tissues.
Pharmacological inhibition of either uPA or selected MMPs decreased atherosclerosis in transgenic uPA mice.
uPA-mediated arterial constriction is a vasomotor process that is mediated by uPA catalytic activity, not by the NH(2)-terminal domains.
Data show that urokinase-type plasminogen activator (uPA) is only expressed in the cumulus cells of immature and in vitro matured cumulus-oocyte complexes (COCs), while uPA receptor (uPAR (show PLAUR Antibodies)) and plasminogen activator inhibitor-1 (PAI-1 (show SERPINE1 Antibodies)) are expressed in both the cumulus cells and the immature and in vitro matured oocytes.
uPA/uPAR (show PLAUR Antibodies) binding is involved in signaling pathways that activate transcription factors that regulate the synthesis of molecules concerned with the arrangement of a particular oviductal microenvironment.
These data indicated that E. coli LPS (show IRF6 Antibodies) led to an increase in u-PA activity and RNA expression of u-PA and u-PAR (show PLAUR Antibodies) in BME-UV1 cells, thus strengthening the role of the PA system during pathological processes.
The plasminogen/plasminogen (show PLG Antibodies) activator/plasmin (show PLG Antibodies) system is activated during gamete interaction and regulates the sperm entry into the oocyte.
stage-dependent regulation of granulosa cell PA and SerpinE2 (show SERPINE2 Antibodies) production, consistent with a role in extracellular matrix remodeling during follicle growth.
This gene encodes a serine protease involved in degradation of the extracellular matrix and possibly tumor cell migration and proliferation. A specific polymorphism in this gene may be associated with late-onset Alzheimer's disease and also with decreased affinity for fibrin-binding. This protein converts plasminogen to plasmin by specific cleavage of an Arg-Val bond in plasminogen. Plasmin in turn cleaves this protein at a Lys-Ile bond to form a two-chain derivative in which a single disulfide bond connects the amino-terminal A-chain to the catalytically active, carboxy-terminal B-chain. This two-chain derivative is also called HMW-uPA (high molecular weight uPA). HMW-uPA can be further processed into LMW-uPA (low molecular weight uPA) by cleavage of chain A into a short chain A (A1) and an amino-terminal fragment. LMW-uPA is proteolytically active but does not bind to the uPA receptor. Alternatively spliced transcript variants encoding different isoforms have been found for this gene.
urokinase-type plasminogen activator
, U-plasminogen activator
, plasminogen activator, urokinase
, plasminogen activator, urinary
, Urinary plasminogen activator, urokinase
, urokinase plasminogen activator preproprotein